Pregabalin Capsule
Product Images NDC 82619-126

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 82619-126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Creekwood Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 01)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 01)
A formula table showing the calculation for creatinine clearance (CLCr), which involves age in years, weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 applied for female patients.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 02)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 02)
Chemical structure of Pregabalin showing the molecule's carbon, hydrogen, nitrogen, and oxygen atoms arranged to depict its chemical formula.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 03)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 03)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for different dosages of Pregabalin (200 mg, 100 mg, 25 mg taken three times a day) compared to placebo. The graph shows separate curves for each treatment group illustrating relative efficacy in pain improvement.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 04)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 04)
A line graph comparing the percent improvement in pain from baseline with the percent of patients improved. It shows two curves: one for Pregabalin 100 mg taken three times a day and one for placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved. Vertical lines highlight specific improvement thresholds around 30% and 50%.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 05)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 05)
A line graph depicting the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares different dosages of Pregabalin (300 mg, 150 mg, 75 mg, taken two times a day) and a placebo, showing a descending trend of patient improvement across increasing pain improvement percentages.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 06)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 06)
A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis represents the percent of patients improved, and the x-axis denotes percent improvement in pain from baseline.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 07)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 07)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows greater improvement for both Pregabalin doses compared to placebo across different levels of pain improvement.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 08)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 08)
A bar chart from studies E1 and E3 showing responder rates (%) for different doses of pregabalin versus placebo. The x-axis lists treatments (placebo, 150 mg/day, 300 mg/day, 600 mg/day), and the y-axis shows responder rates from 0 to 60%. Bars illustrate increasing responder rates with higher pregabalin doses compared to placebo.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 09)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 09)
A line graph depicting the percentage change from baseline in seizure reduction (median values) on the y-axis versus dose in mg/day on the x-axis. It shows data from four studies (E1 BD, E2 TID, E3 BD, E3 TID) with different markers for each study. Significant p-values are noted at various dose levels, with placebo represented at zero dose.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 10)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 10)
A line chart showing the percent of patients improved plotted against percent improvement in pain from baseline for Pregabalin doses of 300 mg, 450 mg, 600 mg daily, and placebo. The chart presents comparative efficacy by dose, with the x-axis representing improvement percentage ranging from 0 to 100 and the y-axis showing percent of patients improved from 0 to 100 percent.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 11)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 11)
A Kaplan-Meier curve comparing the estimated percentage of subjects without loss of therapeutic response (LTR) over 180 days between Pregabalin and placebo groups. The x-axis shows days, and the y-axis shows the estimated percentage of subjects without LTR from 0% to 100%. Pregabalin's curve lies above placebo's throughout the period.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 12)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 12)
A line graph comparing the percentage of subjects improved over time from baseline to week 12, measured by Percent Improved on the y-axis and Percent Improved from Baseline to Week 12 BOCF on the x-axis. Two lines are shown: one for Pregabalin (solid line) and one for Placebo (dotted line), indicating a higher percentage improvement in subjects taking Pregabalin across the observed range.*
FDA Label Image

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 13)

Image (83c13926 F4dd 49f4 Ab82 5b1f41621f19 13)
A line graph comparing the percent of subjects improved over a range of percentage improvements from baseline to Week 16 BOCF for Pregabalin versus Placebo. The graph shows two lines, one solid for Pregabalin and one dashed for Placebo, across plotted percentages improved on the x-axis and the percent of subjects improved on the y-axis.*
FDA Label Image

25mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 14)

25mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 14)
Packaging label for Pregabalin Capsules 25 mg, oral dosage form, containing 90 capsules. Distributed by Creekwood Pharmaceuticals LLC. The label includes storage instructions, prescription status (Rx Only), and a barcode. Manufactured by V-Ensure Pharma Technologies Pvt. Ltd., India.*
FDA Label Image

50mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 15)

50mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 15)
Label of Pregabalin 50 mg capsules, featuring the product name, dosage strength, and quantity of 90 capsules. It shows the NDC number 82619-123-01, manufacturer as V-Ensure Pharma Technologies Pvt. Ltd. (India), and distributor Creekwood Pharmaceuticals LLC (Parsippany, NJ). Storage instructions and dispensing notes are also visible.*
FDA Label Image

75mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 16)

75mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 16)
Label for Pregabalin Capsules 75 mg by Creekwood Pharmaceuticals LLC. The label indicates a prescription drug containing 90 capsules. It includes storage instructions, manufacturer V-Ensure Pharma Technologies Pvt. Ltd., and distributor details. The label features the NDC 82619-124-01 and a barcode.*
FDA Label Image

100mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 17)

100mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 17)
Pregabalin Capsules 100 mg oral capsules in a 90-count package. The label includes NDC 82619-125-01 and highlights that the product is prescription only (Rx Only). It is manufactured by V-Ensure Pharma Technologies Pvt. Ltd. and distributed by Creekwood Pharmaceuticals LLC. Storage instructions and dosage guidance are also noted on the label.*
FDA Label Image

150mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 18)

150mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 18)
Pregabalin Capsules 150 mg oral dosage form label showing a package of 90 capsules. The label includes the NDC 82619-126-01, manufacturer V-Ensure Pharma Technologies Pvt. Ltd., India, and distributor Creekwood Pharmaceuticals LLC, Parsippany, NJ. Storage instructions and regulatory information are also visible.*
FDA Label Image

200mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 19)

200mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 19)
Label for Pregabalin Capsules 200 mg, oral dosage form, distributed by Creekwood Pharmaceuticals LLC. The label states each capsule contains 200 mg of Pregabalin USP and indicates storage instructions. The package contains 90 capsules. Manufactured by V-Ensure Pharma Technologies Pvt. Ltd., India, with a visible barcode and NDC 82619-127-01.*
FDA Label Image

225mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 20)

225mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 20)
Packaging label for Pregabalin Capsules 225 mg by Creekwood Pharmaceuticals LLC. The label indicates it contains 90 capsules, with storage instructions between 20° to 25°C. Manufactured by V-Ensure Pharma Technologies Pvt. Ltd., India, and distributed by Creekwood Pharmaceuticals LLC in Parsippany, NJ.*
FDA Label Image

300mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 21)

300mg-90s (83c13926 F4dd 49f4 Ab82 5b1f41621f19 21)
Label for Pregabalin 300 mg capsules, a human prescription drug for oral use. The package contains 90 capsules. Manufactured by V-Ensure Pharma Technologies Pvt. Ltd., India, and distributed by Creekwood Pharmaceuticals LLC, Parsippany, NJ. The label includes storage instructions and a barcode. The label clearly states Rx only and medication guide advice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.